Bitter pill for Brussels? Trump's fight with Irish pharma

Oskar Fairbairn, Lena Fiedler, Holger Görg and Aoife Hanley

No 196, Kiel Policy Briefs from Kiel Institute for the World Economy (IfW Kiel)

Abstract: • Around 60% of Irish net exports to US are pharma products. • A 200% US tariff would devastate all EU exports, not just Ireland's. • Irish business leaders we interviewed are confident that pharma's competitiveness will ensure its survival

Keywords: US-EU trade; Pharmaceuticals; Ireland; Multinational Firms; US-EU-Handel; Pharmazeutika; Irland; Multinationale Unternehmen (search for similar items in EconPapers)
Date: 2025
New Economics Papers: this item is included in nep-int
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.econstor.eu/bitstream/10419/327994/1/1937472140.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:zbw:ifwkpb:327994

Access Statistics for this paper

More papers in Kiel Policy Briefs from Kiel Institute for the World Economy (IfW Kiel) Contact information at EDIRC.
Bibliographic data for series maintained by ZBW - Leibniz Information Centre for Economics ().